David Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.
David Miklos, MD
Advertisement
Articles by David Miklos, MD
David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.
Advertisement
Latest Updated Articles
CAR T-Cell Therapy Appears Promising in Relapsed/Refractory DLBCLPublished: April 15th 2020 | Updated:
Highlighting CAR T Cell Options for Relapsed/Refractory DLBCLPublished: March 14th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
